Sanhuang Xiexin decoction promotes good functional outcome in acute ischemic stroke

Juexian Song¹* | Xin Chen²* | Yi Lyu³* | Wei Zhuang⁴ | Jing Zhang¹ | Li Gao¹ | Xiaolin Tong⁵

¹Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
²Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
³Department of Anesthesiology, Yunnan Baoshan Anli Hospital, Shanghai, China
⁴Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China
⁵Department of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing, China

Correspondence
Xiaolin Tong, Department of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing, China.
Email: tongxiaolin@vip.163.com

Funding information
Chinese Natural Science Foundation Grants, Grant/Award Number: 81401090; Key Projects of National Natural Foundation of China, Grant/Award Number: 81430097; Beijing Gaoli Famous Doctor Inherit Workstation Project, Grant/Award Number: Jing Zhong Ke [2016] 136

Abstract

Objectives: To explore the efficiency and safety of Sanhuang Xiexin decoction in the treatment of acute ischemic stroke (AIS) patients after endovascular intervention examination.

Methods: In this prospective observational study, 121 AIS patients admitted in our hospital were enrolled from January 2012 to December 2015. They were randomly divided into two groups, 61 patients received Sanhuang Xiexin decoction + basic treatment (SX group) and 60 patients received basic treatment (control group). The prescription of Sanhuang Xiexin decoction was taken in the SX group, with one dose (100 ml), twice a day for 7 days orally. For all patients, blood samples were drawn on the first morning and sixth morning after endovascular intervention examination under fasting state for Fib (fibrinogen), PAgT (platelet aggregation test), CRP (C-reactive protein), and TMAO (trimethylamine oxide) tested. Estimate the changes in plasma Fib, PAGT, CRP, and TMAO levels and the syndrome of fire-heat scores.

Results: The plasma Fib, PAGT, CRP, and TMAO levels in the SX group were significantly lower than those in the control group ($P_{Fib}<0.01$, $P_{PAgT}<0.01$, $P_{CRP}=0.02$, $P_{TMAO}<0.01$). The syndrome of fire-heat scores in the SX group was significantly lower than that in the control group ($p<0.01$). The incidences of ischemic cerebrovascular events within 3 and 6 months after endovascular intervention treatment in the SX group were lower than those in the control group ($P_{3\text{ month}}=0.04$, $P_{6\text{ month}}=0.03$).

Conclusions: The prescription of Sanhuang Xiexin is efficient and safe in the treatment of AIS patients after endovascular intervention examination through reducing the inflammatory factors.

KEYWORDS
acute ischemic stroke, endovascular intervention, inflammatory factors, Sanhuang Xiexin decoction

*These are co-first authors.
1 | INTRODUCTION

Stroke is one of the most common causes of death and disability worldwide (Li, Geng, & Ding, 2017). The treatment of acute ischemic stroke (AIS) is a very complicated process, but the effect of Western medicine treatment is not satisfactory (Xu & Li, 2011). The traditional Chinese medicine has been used in vascular disease treatment for thousands of years in the Asia-Pacific region. It has been proven that the traditional Chinese medicine can play the advantage of treating both root causes and symptoms of inflammatory response in AIS patients with endovascular intervention examination (Zhang et al., 2015).

According to the theory of traditional Chinese medicine, AIS patients with syndromes of fire-heat, such as dry mouth, constipation, yellow urine, and red tongue, should receive clearing heat and purging phlegm treatment (Zou, 1999), so we chose the prescription of Sanhuang Xiexin decoction, which included Coptidis Rhizoma, Rhei Radix et Rhizoma, Scutellariae Radix, Lophatherum Gracile, Bile Arisaema, and Forsythia (Chen, 2008). Sanhuang Xiexin decoction has been demonstrated to have a variety of bioactivities including anti-inflammation (Shih, Chen, Wu, & Lo, 2011), anti-oxidative (Liou, Hsu, Liang, & Yeh, 2012), and anti-atherosclerosis (Wang, Lin, Cheng, & Juo, 2011). In this prospective, randomized, and controlled study, we explored the efficiency and safety of Sanhuang Xiexin decoction in the treatment of AIS patients after endovascular intervention examination.

2 | MATERIALS AND METHODS

2.1 | Participants

From January 2012 to December 2015, 121 patients with AIS who were admitted in the neurology department of our hospital were enrolled in this study. This study was approved by the local ethical committee, and all patients signed informed consents before treatment. They were in accordance with the diagnostic criteria of cerebral infarction approved by the fourth national cerebrovascular academic conference (1995).

Inclusion and exclusion criteria: (1) All enrolled patients underwent endovascular intervention examination (multislice computed tomography angiographic, MSCTA; parameters: 120 kV, 150 mAs, thickness 5 mm, interval 5 mm); (2) all patients met the standards of fire-heat scores (a. tongue: 5 points for red tongue, 6 points for deep red tongue; b. tongue coating: 2 points for thin-yellow coating, 3 points for thick-yellow coating, 4 points for dry coating, 5 points for gray-black-dry coating; c. excrement: 3 points for astriction within 3 days, 4 points for astriction more than 3 days; d. expression: 2 points for irritability, 3 points for agitated and restless, 4 points for delirium; e. face breath odor: 2 points for loud, rough, or dry-red lips, 3 points for flame, panting, or halitosis; f. fever: 3 points for fever; g. pulse: 2 points for powerful pulse; g. mouth feeling: 1 point for bitter taste and dry throat, 2 points for thirst with a predilection for cold drink; h. urine: 1 point for odynuria; Table 1); (3) patients without incomplete hepatic or renal function or severe psychiatric disease; (4) patients without high sensitivity to medicine in this study; (5) all patients were informed by both the experts in the interventional department and the experts in neurology department, and the family members were informed of the disease and signed the informed consent to be examined by cerebral angiography and to be given the decoction of Sanhuang Xiexin.

2.2 | Therapeutic methods

All patients who were enrolled in this study were randomly divided into Sanhuang Xiexin decoction group (SX group, n = 61) and control group (n = 60). Basic treatment with drugs for antiplatelet and improving circulation was used in the control group (aspirin 300 mg and clopidogrel 75 mg were used pre-endovascular intervention treatment with once a day for 3–5 days; the same dose was used post-endovascular intervention therapy; aspirin 300 mg reduced to 100 mg 6 weeks after endovascular intervention therapy). In the SX group, the prescription of Sanhuang Xiexin decoction (Coptidis Rhizoma, Rhei Radix et Rhizoma, Lophatherum Gracile, Bile Arisaema, and Forsythia (2:1:2:2:2) were thoroughly decocted in water for 2 hr (1:15, w/v), then the gruffs were extracted three times using boiling water (1:10, w/v), for another 2 hr. Finally, all the herbs were merged and concentrated to 1.0 g/ml; Wei, Tao, Cui, Jiang, Qian, & Duan, 2017; Zhang, Wang, Ma, Zhu, & Wang, 2013) was taken on the basis of basic treatment, with one dose (100 ml), twice a day for 7 days orally.

2.3 | Study design

According to the criteria of diagnosis and curative effect evaluation of stroke (Trial) (State Administration of Traditional Chinese Medicine, 1995), the standards of fire-heat scores were used as Table 1:

| Items               | Symptoms                              | Scores |
|---------------------|---------------------------------------|--------|
| Tongue              | Red tongue                            | 5      |
|                     | Deep red tongue                       | 6      |
| Tongue coating      | Thin-yellow coating                   | 2      |
|                     | Thick-yellow coating                  | 3      |
|                     | Dry coating                           | 4      |
|                     | Gray-black-dry coating                | 5      |
| Excrement           | Astriction within 3 days              | 3      |
|                     | Astriction more than 3 days           | 4      |
| Expression          | Irritability                          | 2      |
|                     | Agitated and restless                 | 3      |
|                     | Delirium                              | 4      |
| Face breath odor    | Loud, rough, or dry-red lips          | 2      |
|                     | Flame, panting, or halitosis          | 3      |
| Fever               | Fever                                 | 3      |
| Pulse               | Rough pulse                           | 2      |
| Mouth feeling       | Bitter taste and dry throat           | 1      |
|                     | Thirst with a predilection for cold drink | 2      |
| Urine               | Odynuria                              | 1      |

TABLE 1 Standards of fire-heat scores
SONG et al. (1996), all patients were evaluated by the same group of trained neurologists with the standard of syndrome fire-heat scores (Wang, Han, & Chen, 1996).

The blood samples were drawn on the first morning and the sixth morning after endovascular intervention therapy under fasting state for Fib (Fibrinogen), PAgT (platelet aggregation test), CRP (C-reactive protein), and TMAO (trimethylamine oxide) tested. Observing the changes in plasma Fib, PAgT, CRP, and TMAO levels and the syndrome of fire-heat scores.

The patients were followed up for 6 months after the endovascular intervention treatment to observe the occurrence of cerebrovascular events within 3 and 6 months, including transient ischemic attack, acute ischemic stroke, and vascular restenosis.

2.4 | Statistical analyses

Statistical analyses were performed using SPSS 17.0 software (IBM SPSS, Armonk, NY, USA). The continuous variables fitting the normal distribution were expressed as mean ± standard deviation (SD). The Student’s t test was used for continuous variables, and the chi-squared test was used for categorical variables. p < 0.05 was considered to be statistically significant.

3 | RESULTS

3.1 | Comparison of plasma Fib, PAgT, CRP, and TMAO and fire-heat scores in the first morning after endovascular intervention treatment

The two groups were comparable with no significant difference in gender, age, and complications. There were no significant differences between the SX group and the control group in the plasma levels of Fib, PAgT, CRP, and TMAO and syndrome of fire-heat scores in the first morning after endovascular intervention treatment (p > 0.05; Table 2). The plasma Fib, PAgT, CRP, and TMAO levels in the SX group were significantly lower than those in the control group in the sixth morning after endovascular intervention treatment (PFib < 0.01, PPAgT < 0.01, PCR = 0.03, PTMAO < 0.01). The syndrome of fire-heat scores in the SX group was also lower than that in the control group (p < 0.01; Table 3).

3.2 | Comparison of the incidence of cerebrovascular events within 3 months and 6 months after endovascular intervention treatment

The total incidence of cerebrovascular events (transient ischemic stroke, acute ischemic stroke, and vascular restenosis) in the SX group was lower than that in the control group within 3 and 6 months after endovascular intervention treatment (P3month = 0.01, P6month = 0.03; Table 4).

### Table 2

The serum levels of Fib, PAgT, CRP, and TMAO and fire-heat scores in the first morning after endovascular intervention treatment ($\bar{x} \pm s, n [%])$

|                      | SX group (n = 61) | Control group (n = 60) | p Value |
|----------------------|------------------|------------------------|---------|
| Age                  | 59.15 ± 13.76    | 60.78 ± 12.13          | 0.78    |
| Male                 | 33 (55.00)       | 32 (53.33)             | 0.86    |
| Hypertension         | 28 (45.90)       | 29 (48.33)             | 0.79    |
| Diabetes             | 14 (23.33)       | 13 (21.31)             | 0.87    |
| Heart disease        | 9 (14.75)        | 9 (15.00)              | 0.97    |
| Smoking              | 32 (52.46)       | 30 (50.00)             | 0.79    |
| Drinking             | 18 (29.51)       | 15 (25.00)             | 0.58    |
| Fib                  | 4.20 ± 0.90      | 4.15 ± 0.61            | 0.74    |
| PAgT                 | 47.60 ± 7.28     | 45.73 ± 6.22           | 0.67    |
| CRP                  | 5.60 ± 2.47      | 5.53 ± 2.84            | 0.62    |
| TMAO                 | 276.58 ± 48.59   | 287.82 ± 52.18         | 0.53    |
| Syndrome of fire-heat scores | 13.20 ± 6.50 | 12.04 ± 6.973          | 0.69    |

Note. The clinical data of the two groups were compared, the p values were >0.05, and there were no statistical differences. CRP: C-reactive protein; Fib: fibrinogen; PAgT: platelet aggregation test; SX: Sanhuang Xiexin decoction; TMAO: trimethylamine oxide.

### Table 3

The serum levels of Fib, PAgT, CRP, and TMAO and fire-heat scores in the sixth morning after endovascular intervention treatment,$\bar{x} \pm s$

|                      | SX group (n = 61) | Control group (n = 60) | p Value |
|----------------------|------------------|------------------------|---------|
| Fib                  | 2.62 ± 0.97      | 3.72 ± 0.91            | <0.01   |
| PAgT                 | 33.49 ± 14.70    | 44.53 ± 14.71          | <0.01   |
| CRP                  | 3.22 ± 2.10      | 4.38 ± 2.14            | 0.03    |
| TMAO                 | 145.04 ± 32.12   | 231.58 ± 47.43         | <0.01   |
| Syndrome of fire-heat scores | 6.84 ± 3.60 | 11.16 ± 2.85           | <0.01   |

Note. CRP: C-reactive protein; Fib: fibrinogen; PAgT: platelet aggregation test; SX: Sanhuang Xiexin decoction; TMAO: trimethylamine oxide.
ischemic stroke, acute ischemic stroke, and vascular restenosis. Inflammation plays an important role in the process of ischemic stroke, and inflammatory factors are hallmarks of inflammation. The incidence of ischemic cerebrovascular events in ischemic stroke patients within 3 and 6 months after endovascular intervention treatment, n (%)

| Cerebrovascular events within 3 months | SX group (n = 61) | Control group (n = 60) | p Value |
|----------------------------------------|------------------|-----------------------|---------|
| 2 (3.28)                               | 10 (16.67)       | 0.01                  |

Note. SX: Sanhuang Xiexin decoction; cerebrovascular events: transient ischemic stroke, acute ischemic stroke, and vascular restenosis.

4 | DISCUSSION

In this study, we found (a) Sanhuang Xiexin decoction could significantly decrease the levels of inflammatory factors including Fib, PAgT, CRP, and TMAO in ischemic stroke patients; (b) in addition, Sanhuang Xiexin decoction could also reduce the syndrome of fire-heat scores; (c) moreover, Sanhuang Xiexin decoction could reduce the incidence of ischemic cerebrovascular events in ischemic stroke patients within 3 and 6 months after endovascular intervention treatment as well.

Inflammation plays an important role in the process of ischemic stroke, and inflammatory factors are hallmarks of inflammation. The prescription of Sanhuang Xiexin decoction has the functions of clearing away heat and toxic materials, resolving phlegm and dredging collaterals, clearing bowels and purging diarrhea, regulating intestinal flora through purgation, reducing the production of TMAO, reducing platelet aggregation and inflammatory reaction, and improving stroke and prognosis. This study showed that the Sanhuang Xiexin decoction could effectively reduce the blood levels of Fib, CRP, PAgT, and TMAO and the fire-heat scores of AIS patients when compared with the control group, which proved the clinical efficacy of this traditional Chinese medicine prescription.

Sanhuang Xiexin decoction was first described in “On Cold Damage (Shang Han Lun)”, a famous traditional Chinese medicine book, and the preparation of it was also recorded in detail (Li, 1997). Coptidis Rhizoma (the Ranunculaceae family, rhizomes of Coptis Chinensis Franch), Rhein Radix et Rhizoma (the Polygonaceae family, rhizomes of Rheum officinale Baill), and Scutellariae Radix (the Labiatae family, roots of Scutellaria baicalensis Georgi) are the most important components of it. Palmatine, berberine, jatrorrhizine, and coptisine are the main functional components in Coptidis Rhizoma which have many pharmacological effects including anti-inflammatory, anti-diabetic, antioxidative, and hypercholesterolemic effects (Yuan, Tu, Ye, & Wu, 2006). Anthraquinones which contain emodin, rhein, and aloe-emodin are the main active constituents of Rhein Radix et Rhizoma. They not only have antimicrobial and antiviral properties but also can increase motor locomotion of the large intestine (Semple, Pyke, & Reynolds, 2011). The indicators of quality control for Scutellariae Radix are usually baikalin, wogonosides, and wogonin in view of their various pharmacological effects of anti-inflammatory, antibacterial, anti-arithmetic, anti-malaria, antioxidative, and antitumor activities, and free radical scavenging (Gao, Huang, Yang, & Xu, 1999). There have been a number of studies to detect the effects of Sanhuang Xiexin decoction on inflammation. In animal studies, the results indicated that the decoction of Sanhuang Xiexin could significantly increase IL-10 production as well as decrease TNF-α production which demonstrated that the Sanhuang Xiexin decoction had significant anti-inflammatory effects (Zhang, Ma, Wang, & Wang, 2013). Lophatherum Gracile contains triterpenes and steroids, including arundoin, imperata, taraxerol, beta-sitosterol, and camp-esterol. It has antipyretic, diuretic, and antibacterial effects (Chen, 2014). Lophatherum Gracile is also rich in flavonoids, including orientin, isoorientin, and vitexin; it can inhibit the expression of NO and iNOS which is mediated by LPS in macrophages; and it also can significantly reduce the expression of TNF, IL-1, and IL-6 (Yang et al., 2017). Bile Arisaema can remove heat-phlegm which is effective for stroke (Bai et al., 2010). It can inhibit the production of pro-inflammatory cytokines, including IL-6 and tumor necrosis factor (TNF); moreover, it also can inhibit the expression of mRNA and protein during the production of cytokine (Ahn, 2012). Forsythia has the liver protective, antipyretic, anti-inflammatory, and diuretic effects (Yuan et al., 2017).

In summary, this prospective randomized controlled clinical study showed that Sanhuang Xiexin decoction was effective and safe in the treatment of acute cerebrovascular disease, and it could relieve constipation, thick-yellow tongue coating, and other clinical symptoms. It could also reduce the inflammatory factors after AIS. Besides, this traditional Chinese medicine prescription had an inhibitory effect on the inflammatory activity after endovascular intervention examination in patients with AIS without side effects. However, we did not record the cerebral angiographic data, and we...
could not compare the efficacy between different types of AIS. In further investigation, we should continue to improve the composition in this prescription to get better curative effect, and the mechanism of this prescription should also be explored.

ACKNOWLEDGMENTS

This work was supported by the Chinese Natural Science Foundation Grants 81401090 (for Juexian Song), Key Projects of National Natural Foundation of China (81430097) (for Xiaolin Tong), and Beijing Gaoli Famous Doctor Inherit Workstation Project (Jing Zhong Ke [2016] 136) (for Li Gao).

CONFLICT OF INTEREST

None declared.

ORCID

Xiaolin Tong https://orcid.org/0000-0002-9873-4154

REFERENCES

Ahn, J. C. (2012). Anti-inflammatory activity of the oriental herb medicine, Arisaema cum Bile, in LPS-induced PMA-differentiated THP-1 cells. *Immunopharmacology and Immunotoxicology*, 34(3), 379–384.

Bai, Z. L., Ren, Y. Z., Chen, Y. L., Du, J. L., Liang, H., Peng, X. J., ... Qu, X. Y. (2010). Pharmacological study of arisaema cum bile. *Modern Chinese Medicine*, 12(4), 15–18.

Chen, R. C. (2008). Survey of Xiexin Tang categorized formulas. *Journal of Traditional Chinese Medicine*, 7(7), 19–22.

Chen, Y. (2014). Pharmacological study of folsa bambosae. *Asia-Pacific Traditional Medicine*, 7(4), 89–90.

Choi, J. H., Cha, J. K., & Huh, J. T. (2014). Adenosine diphosphate-induced platelet aggregation might contribute to poor outcomes in atrial fibrillation-related ischemic stroke. *Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association*, 23(3), e215–e220. https://doi.org/10.1016/j.jsctrd.2013.10.011

Das, S., Roy, S., Kaul, S., Jyothy, A., & Munshi, A. (2004). CRP gene (1059G>C) polymorphism and its plasma levels in ischemic stroke and hemorrhagic stroke in a South Indian population. *Inflammation*, 37(5), 1683–1688.

Davalos, D., & Akassoglou, K. (2012). Fibrinogen as a key regulator of inflammation in disease. *Seminars in Immunopathology*, 34(1), 43–62. https://doi.org/10.1007/s00281-011-0290-8

Gao, Z., Huang, K., Yang, X., & Xu, H. (1999). Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of *Scutellaria baicalensis* Georgi. *Biochimica Et Biophysica Acta*, 1472(3), 643–650. https://doi.org/10.1016/S0006-8026(99)00152-X

Li, T. K. (1997). Tentative study of solvent for decocting drug in treaties on cold damage diseases. *Research of Traditional Chinese Medicine*, 1, 31–32.

Li, W. A., Geng, X., & Ding, Y. (2017). Stroke is a global epidemic: New developments in clinical and translational cerebrovascular diseases research. *Neurological Research*, 39(6), 475–476. https://doi.org/10.1080/01616412.2017.1330307

Liou, S. F., Huang, J., J., Liang, J. C., & Yeh, J. L. (2012). San-Huang-Xie-Xin-Tang protects cardiomyocytes against hypoxia/reoxygenation injury via inhibition of oxidative stress induced apoptosis. *Journal of Natural Medicines*, 66(2), 311–320.

Schmalbach, B., Stepanow, O., Jochens, A., Riedel, C., Deuschl, G., & Kuhlenbäumer, G. (2015). Determinants of platelet-leukocyte aggregation and platelet activation in stroke. *Cerebrovascular Disease*, 39(3–4), 176–180. https://doi.org/10.1159/000375396

Semple, S. J., Pyke, S. M., & Reynolds, G. D. (2011). In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. *Antiviral Research*, 49(3), 169–178.

Shih, Y. T., Chen, I. J., Wu, Y. C., & Lo, Y. C. (2011). San-Huang-Xie-Xin-Tang protects against activated microglia- and 6-OHDA-induced toxicity in neuronal SH-SYSY cells. *Evidence-Based Complementary and Alternative Medicine: Ecam*, 2011, 429384. https://doi.org/10.1093/ecam/nep025

State Administration of traditional Chinese medicine, a group of encephalopathy and emergencies. (1996). Criteria for the diagnosis and efficacy of Apoplexy (Trial). *Journal of Beijing University of Traditional Chinese Medicine*, 19(1), 55–56.

Wang, X. Z., Han, Q. Y., & Chen, H. H. (1996). The dictionary of stroke in China (pp. 1044–1048), Beijing: People’s Medical Publishing House.

Wang, Y. S., Lin, R. T., Cheng, H. Y., & Juo, S. H. (2011). Anti-atherogenic effect of San-Huang-Xie-Xin-Tang a traditional Chinese medicine, in cultured human aortic smooth muscle cells. *Journal of Ethnopharmacology*, 133(2), 442–447. https://doi.org/10.1016/j.jep.2010.10.018

Wei, X. Y., Tao, J. H., Cui, X., Jiang, S., Qian, D. W., & Duan, J. A. (2017). Comparative pharmacokinetics of six major bioactive components in normal and type 2 diabetic rats after oral administration of Sanhuang XieXin Decoction extracts by UPLC-TQ MS/MS. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*, 1061-1062, 248-255.

Xu, A. Z., & Li, Z. (2011). Research Progress on combination of traditional Chinese and Western medicine in the treatment of cerebrovascular disease. *China Practical Medical*, 6(25), 246–247.

Yang, J. H., Choi, M. H., Yang, S. H., Cho, S. S., Park, S. J., Shin, H. J., & Kl, S. H. (2017). Potent Anti-inflammatory and antiadipogenic properties of bambuck (Sasa coreana Nakai) leaves extract and its major constituent flavonoids. *Journal of Agricultural and Food Chemistry*, 65(31), 6665–6673.

Yuan, A., Gong, L., Luo, L., Dang, J., Gong, X., Zhao, M., ... Peng, C. (2017). Revealing anti-inflammatory mechanism of water-extract and oil of *Forsythiae fructus* on carrageenan-Induced edema rats by serum metabolomics. *Biochemistry & Pharmacotherapy*, 2017(95), 929–937. https://doi.org/10.1016/j.biopharm.2017.09.009

Yuan, L., Tu, D., Ye, X., & Wu, J. (2006). Hypoglycemic and hypcholesterolemic effects of Coptis Chinesis Franch inflorescence. *Plant Foods for Human Nutrition*, 61(3), 139–144. https://doi.org/10.1007/s11130-006-0023-7

Zacharowski, K., Zacharowski, P. A., Friedl, P., Henning, R., Emeis, J. M., & Petzelbauer, P. (2007). The effects of the fibrin-derived peptide Bbeta(15–42) in acute and chronic rodent models of myocardial ischemia–reperfusion. *Shock*, 27(6), 631–637.

Zhang, Q., Wang, C. H., Ma, Y. M., Zhu, E. Y., & Wang, Z. T. (2013). UPLC-ESI/MS determination of 17 active constituents in two categorized formulas of traditional Chinese medicine, Sanhuang XieXin Tang and FuXi XieXin Tang: application in comparing the differences in decocitions and macerations. *Biomedical chromatography*, 27(8), 1079–1088.

Zhang, R., Jiang, F., Chen, C. S., Wang, T., Feng, J., Tao, T., & Qin, X. (2015). Serum levels of IL-1β, IL-6, TGF-β, and MMP-9 in patients undergoing carotid artery stenting and regulation of MMP-9 in a new in vitro model of THP-1 cells activated by stenting. *Mediators of Inflammation*, 2015, 956082.
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., & Hazen, S. (2016). Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell, 65(1), 111–124. https://doi.org/10.1016/j.cell.2016.02.011

Zou, Y. H. (1999). Professor Wang Yongyan’s experience in the treatment of acute apoplexy by using the method of phlegm in the treatment of acute stroke. Journal of Beijing University of Traditional Chinese Medicine, 22(4), 68–69.

How to cite this article: Song J, Chen X, Lyu Y, et al. Sanhuang Xiexin decoction promotes good functional outcome in acute ischemic stroke. Brain Behav. 2019;9:e01185. https://doi.org/10.1002/brb3.1185